NanoVation Therapeutics™
Allison Enjetti, MSc, serves as a Senior Project Manager at NanoVation Therapeutics™ since February 2024, following experience as a Project Manager at AbCellera from April 2020 to December 2023. Previous roles include Research Program Manager at The University of British Columbia's Faculty of Medicine and Research Coordinator at the British Columbia Centre for Excellence in HIV/AIDS. Additionally, Allison worked as an Activities Coordinator for the ACT Consortium and held various positions at USAID, including Program Analyst and Program Assistant for the President's Malaria Initiative. Early career highlights include serving as Program Manager and Community Outreach Specialist for Health Brigade and assisting in HR and office administration at Mitsubishi UFJ Trust & Banking Corporation. Allison holds a Master of Science in Control of Infectious Diseases from the London School of Hygiene and Tropical Medicine and a dual Bachelor’s degree in Biology and Religious Studies from Virginia Commonwealth University.
This person is not in the org chart
This person is not in any teams
NanoVation Therapeutics™
NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases. NTx is delivering tomorrow's genetic medicines, today. For more information, please visit nanovationtx.com.